Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$16.79 - $20.88 $25.3 Million - $31.4 Million
-1,505,200 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$10.69 - $18.2 $16.1 Million - $27.4 Million
1,505,200 New
1,505,200 $24.8 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $770M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Frazier Management LLC Portfolio

Follow Frazier Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Management LLC with notifications on news.